IRVINE, Calif., Oct. 30, 2012 /PRNewswire/ -- GeneTex Inc., a leading manufacturer of antibodies and antibody-related reagents, will be attending the annual meeting of the America Society for Cell Biology (ASCB) from December 15-19 in San Francisco, CA. The ASCB was founded in 1960 as an inclusive community of cell biologists and is dedicated to advancing scientific discovery, advocating sound research policies, improving education, promoting professional development and promoting diversity in the workforce.
The meeting will feature over 100 scientific sessions and 3,000 poster presentations covering a variety of scientific areas including cancer cell biology, neurodegeneration, cellular stress and protein folding, as well as a keynote symposium led by Steven Chu, the U.S. Secretary of Energy, and Arthur D. Levinson, the Chair of Genentech, Inc. and Apple Inc. Attendees will also have the opportunity to visit a variety of commercial and nonprofit exhibits to learn about new products and services.
"I am thrilled to present our products to such a diverse group of scientists," says Stephen Kendall, Ph.D., GeneTex's Director of US Sales and Marketing. "We have recently developed antibodies against several exciting new targets that I am certain will be of interest to the conference attendees."
GeneTex's catalog currently includes over 55,000 primary antibodies spanning a variety of research areas with a particular focus on cancer, hypoxia and stem cell research. GeneTex also offers a variety of related reagents including Turbolink Antibody Conjugation Kits and Easyblot second step reagent for the elimination of masking bands in IP experiments. GeneTex's exhibit will be located at booth 1043, and representatives will be available throughout the conference to discuss their products.
GeneTex is an antibody manufacturing company that was founded by a group of renowned academic scientists in 1997. GeneTex strives to produce the highest quality antibodies and reagents. Their primary antibodies and secondary antibodies are created through a process involving extensive research, development and validation.
Copyright©2012 PR Newswire.
All rights reserved